Join the Botox group to help and get support from people like you.
Botox News
Targeted Diagnostic Botox Injections Can Identify Trigger Sites for Migraine
THURSDAY, May 9, 2024 – Diagnostic targeted Botox injections have high positive predictive value for migraine trigger site localization, according to a study published in the May issue of Plastic...
FDA Medwatch Alert: Counterfeit Versions of Botox Found in Multiple States
April 16, 2024 -- FDA is alerting health care professionals and consumers that unsafe counterfeit versions of Botox (botulinum toxin) have been found in multiple states and administered to consumers ...
CDC Warns of 19 Cases of Botched Botox Shots in 9 States
TUESDAY, April 16, 2024 – Counterfeit or mishandled Botox shots have triggered harmful reactions in 19 people in nine states, U.S. health officials warned Monday. In its alert, the U.S. Centers for...
FDA Approves Expanded Botox (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of Botox® ...
Botox (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
NORTH CHICAGO, Ill., Feb. 10, 2021 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved Botox® for the treatment of ...
FDA Approves Expanded Botox (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
NORTH CHICAGO, Ill., July 9, 2020 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License...
FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
DUBLIN, Oct. 24, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application...
FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
DUBLIN, June 21, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental biologics application (sBLA) for...
FDA Approves Botox (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity
DUBLIN, Jan. 22, 2016 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved Botox...
FDA Approves Botox Cosmetic to Improve the Appearance of Crow’s Feet Lines
WEDNESDAY, September 11, 2013 – The U.S. Food and Drug Administration today approved a new use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to...
FDA Approves Botox to Treat Overactive Bladder
January 18, 2013 – The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately...
FDA Approves Botox to Treat Specific Form of Urinary Incontinence
SILVER SPRING, Md., Aug. 24, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Botox (onabotulinumtoxinA) injection to treat urinary incontinence in people with...
FDA Approves Botox to Treat Chronic Migraine
SILVER SPRING, Md., Oct. 15 – The U.S. Food and Drug Administration today approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine. Chronic migraine...
Botox (onabotulinumtoxinA) Receives FDA Approval for Treatment of Upper Limb Spasticity in Adults
IRVINE, Calif.--(BUSINESS WIRE)--Mar 10, 2010 - Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved Botox (onabotulinumtoxinA) for the treatment of...
FDA Medwatch Alert: Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B)
FDA notified healthcare professionals that after an ongoing safety review initiated in February 2008, the manufacturers of licensed botulinum toxin products will be required by FDA to strengthen...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Chronic Migraine, Facial Wrinkles, Hyperhidrosis, Migraine Prevention, Migraine Prophylaxis, Overactive Bladder, Urinary Incontinence